



**INTELLECTUAL
PROPERTY INDIA**
PATENTS | DESIGNS | TRADE MARKS
GEOGRAPHICAL INDICATIONS



Application Filing Receipt

**Government of India
Patent Office**

Intellectual Property Office Building,
Plot No. 32, Sector 14, Dwarka,
New Delhi-110075
Phone- 011-28032253, 25300200
Fax: 011-28034301, 28034302
e-mail: delhi-patent@nic.in

CBR Number : 13896

CBR date: 17-08-2016

Application Type: ORDINARY APPLICATION

Priority Number: PCT//

Priority Date: 01/01/1900

Priority Country: -----

To,

INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE

S. MAJUMDAR & CO., 5 Harish Mukherjee Road, Kolkata - 700 025, West Bengal, India

Received documents purporting to be an application for patent numbered 201631028078 dated 17-08-2016 by INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE of 2A & 2B, Raja S.C. Mallick Road, Kolkata - 700 032, West Bengal, India relating to NANOPARTICLE FORMULATION FOR COMPLETE INHIBITION OF AMYLOID FIBRILLATION AND DISSOLUTION OF AMYLOID FIBRIL together with the Complete and fee(s) of ₹40000 (Forty Thousand only).

Note:

1. In case of Patent Application accompanied by a Provisional Specification, a complete Specification should be filed within 12 months from the date of filing of the Provisional Specification, failing which the application will be deemed to be abandoned under Section 9(1) of the Patent Act, 1970.
2. You may withdraw the application at any time before the grant of patent, if you wish so. If, in addition to withdrawal, you also wish to prevent the publication of application in the Patent Office Journal, the application should be withdrawn within fifteen months from the date of priority or date of filing, whichever is earlier.
3. If not withdrawn, your application will be published in the Patent Office Journal after eighteen months from the date of priority or date of filing, whichever is earlier.
4. If you wish to get your application examined, you should file a request for examination in Form-18 within 48 months from the date of priority or date of filing, whichever is earlier, failing which the application will be treated as withdrawn by the applicant under Section 11(B)(4) of the Patent Act, 1970.

(For Controller of Patents)

भारत सरकार
GOVERNMENT OF INDIA
संचार और सूचना प्रौद्योगिकी मंत्रालय
MINISTRY OF COMMUNICATIONS AND INFORMATION TECHNOLOGY
इलेक्ट्रॉनिकी और सूचना प्रौद्योगिकी विभाग
DEPARTMENT OF ELECTRONICS AND INFORMATION TECHNOLOGY
Website: www.deity.gov.in

संख्या
No.....

दिनांक
Date.....

DeitY/IPR/IVB/330/2015

07.10.2015

Dear Sir,

Regarding your application of the patent titled "Metabolite quantitation package with iterative estimation algorithm for proton and phosphorous magnetic resonance spectroscopy signals" to Department of Electronics and Information Technology (Deity). You have mentioned the proposed owners of the proposed patent to be Deity and National Brain Research Centre (NBRC).

2. We have to bring to your knowledge the guidelines for managing IPR of DeitY as per approved terms & conditions are as follows:

- i) The IPR arising out of sponsored project(s) will be with grantee institution(s). While the patent may be taken in the name(s) of inventor(s), the institution(s) shall ensure that the IPR is assigned to institution(s). In cases where the funding/resourcing of researchers have been done jointly with other organizations, the IP rights would be appropriately shared among them.
- ii) The Government of India/Govt. bodies (including its PSUs, Govt. autonomous societies & section 25 companies) shall have right to obtain a royalty-free license for the Intellectual Property for deployment/use of the same for non-commercial purposes. However, in case, IP is proposed for commercial usage, the terms of licensing may be mutually agreed with the grantee institution(s) possessing IPR.
- iii) The grantee institution shall submit the financial requirements for filing of IPR as part of the R&D proposal. The contingency head could be used for provisioning of the expenditure for filing of IPR with a ceiling of Rs. 15 Lakhs for the cost of initial filing, but excluding for the annuity fee. International Patent filing will be permitted. The amount will be released based on the recommendations of PRSG constituted by DeitY for the concerned project. If, for any reason, it is not possible to meet the expenses from the project grant, like in the case of the need for filing of IPR arising after the closure of the project, an application may be made separately by the institution to DeitY for sanction/ reimbursement of the expenses incurred in filing of the IPR.

1 of 2



राष्ट्रीय इ-गवर्नेंस योजना
National e-Governance Plan

भारत सरकार
GOVERNMENT OF INDIA
संचार और सूचना प्रौद्योगिकी मंत्रालय
MINISTRY OF COMMUNICATIONS AND INFORMATION TECHNOLOGY
इलेक्ट्रॉनिकी और सूचना प्रौद्योगिकी विभाग
DEPARTMENT OF ELECTRONICS AND INFORMATION TECHNOLOGY
Website: www.deity.gov.in

संख्या
No.....

दिनांक
Date.....

- iv) The grantee institution shall inform DeitY about the patents filed/obtained and IPR arising out of the R&D project on annual basis over the project duration and subsequent 5 years period after the project closure.
 - v) The grantee institution shall provide information to DeitY about trading/ selling/ transferring /licensing the IP rights, within a period of 6 weeks from conclusion of the agreement relating to such a commercial event.
 - vi) The grantee institution shall take appropriate licence in case of export of 'Special Chemicals, Organisms, Materials, Equipment and Technologies' (SCOMET) items as per the prevailing provisions of Foreign Trade Policy from Directorate General of Foreign Trade, under Department of Commerce, Govt. of India.
 - vii) As the R& D is supported by public fund, the grantee institution should ensure that the interests of India and its citizens are fully protected, while licensing of patents/transfer or commercialization of technology.
 - viii) The institution is permitted to retain the benefits and earnings arising out of the IPR for plough back to pursue research/research related activities.
 - ix) Notwithstanding the above, DeitY reserves the right to take over ownership of the rights of the Intellectual property arising out of this project, in the interest of the Indian sovereignty, without any compensation to the grantee institution.
3. Accordingly you have to exercise your choice for filing the IPR arising out of sponsored project of NBRC for the ownership.(Kindly see the above guidelines)
 4. Kindly send your request through Head of the division and also PI of the sponsored project urgently. We are in process of filing the patent.

With regards


Anil Kumar Sagar
Scientist 'B'

✓ K.V.S. Kameswara Rao, Registrar
NBRC(Deemed University)
NH-08, Manesar-122051(Haryana)

CC:
Prof Pravat Mandal, NBRC
NH-08, Manesar-122051(Haryana)

2 of 2



राष्ट्रीय ई-गवर्नेंस योजना
National e-Governance Plan

Public services closer home

Controller General of Patents, Designs & Trade
Marks



सत्यमेव जयते

G.A.R.6
[See Rule 22(1)]
RECEIPT



INTELLECTUAL
PROPERTY INDIA
PATENTS | DESIGNS | TRADE MARKS
GEOGRAPHICAL INDICATIONS

Docket No 47759

Date/Time 2019/05/17 16:48:00

SUNDARSHAN KUMAR BANSAL 52,
Sukhdev Vihar, Mathura Road Email:
unitedpatent@unitedipr.com

Sl. No.	Ref. No./Application No.	App. Number	Amount Paid	C.B.R. No.	Form Name	Fee Payment	Remarks
1	201911019667	TEMP/E-1/20514/2019-DEL	8000	15393	FORM 1	Full	A METHOD AND A SYSTEM USING MULTI-MODAL NEUROIMAGING FOR EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE

Transaction ID	Payment Mode	Challan Identification Number	Amount Paid	Head of A/C No
N-0000508822	Online Bank Transfer	1705190004361	8000.00	1475001020000001

Total Amount : ₹ 8000

Amount in Words: Rupees Eight Thousand Only

Received from SUNDARSHAN KUMAR BANSAL the sum of ₹ 8000 on account of Payment of fee for above mentioned Application/Forms.

* This is a computer generated receipt, hence no signature required.

Print

Home

About Us

Contact Us

Welcome SUBHATOSH MAJUMDAR [Sign out](#)

PATENT OFFICE
INTELLECTUAL PROPERTY BUILDING
Plot No. 32, Sector 14, Dwarka, New Delhi-
110075
Tel No. (091)(011) 28034304-06 Fax No. 011
28034301,02
E-mail: delhi-patent@ipc.in
Web Site: www.ipindia.gov.in



सत्यमेव जयते

G.A.R.6
(See Rule 22(1))
RECEIPT



Docket No 2328

Date/Time 21/01/2015

To
SUBHATOSH MAJUMDAR

Userid: user040100

5 HARISH MUKHERJEE ROAD

CBR Detail:

Sr. No.	Ref. No./App/SEARCH No.	App. Number	Amount Paid	C.B.R. No.	Form Name	Remarks
1	189/DEL/2015		19200	1629	FORM 1	A CAPILLARY-ELECTRODE DEVICE FOR SIMULTANEOUS INJECTION AND NEURONAL RECORDINGS FROM THE BRAIN

TransactionID	Payment Mode	Challan Identification Number	Amount Paid	Head of A/C No
N-0090081787	Online Bank Transfer	02806342101201550443	19200.00	1475001020000001

Total Amount : ₹ 19200

Amount in Words: Rupees Nineteen Thousand Two Hundred Only

Received from SUBHATOSH MAJUMDAR the sum of ₹ 19200 on account of Payment of fee for above mentioned Application/Forms.

* This is a computer generated receipt, hence no signature required.

[Print](#)[Home](#) [About Us](#) [Contact Us](#)



US009868960B2

(12) **United States Patent**
Sinha et al.

(10) **Patent No.:** US 9,868,960 B2
(45) **Date of Patent:** Jan. 16, 2018

(54) **PLACENTAL LIKE ALKALINE
PHOSPHATASE (PLAP) PROMOTER
MEDIATED CELL TARGETING**

(71) Applicants: **DEPARTMENT OF
BIOTECHNOLOGY**, New Delhi (IN);
**NATIONAL BRAIN RESEARCH
CENTRE**, Haryana (IN); **ALL INDIA
INSTITUTE OF MEDICAL
SCIENCES**, New Delhi (IN)

(72) Inventors: **Subrata Sinha**, Haryana (IN); **Imran
Khan**, New Delhi (IN); **Mohammad
Khalid Zakaria**, New Delhi (IN);
Kunzang Chosdol, New Delhi (IN);
Parthaprasad Chattopadhyay, New
Delhi (IN)

(73) Assignees: **National Brain Research Centre**,
Haryana (IN); **All India Institute of
Medical Sciences**, New Delhi (IN)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: 14/772,361

(22) PCT Filed: May 10, 2014

(86) PCT No.: PCT/IB2014/061350

§ 371 (c)(1),

(2) Date: Sep. 2, 2015

(87) PCT Pub. No.: WO2014/181314

PCT Pub. Date: Nov. 13, 2014

(65) **Prior Publication Data**

US 2016/0053279 A1 Feb. 25, 2016

(30) **Foreign Application Priority Data**

May 10, 2013 (IN) 1400/DEL/2013

(51) **Int. Cl.**

C12N 15/52 (2006.01)

C12N 15/85 (2006.01)

A61K 48/00 (2006.01)

C12N 15/11 (2006.01)

C12N 15/63 (2006.01)

C12N 15/113 (2010.01)

(52) **U.S. Cl.**

CPC C12N 15/85 (2013.01); A61K 48/0058
(2013.01); C12N 15/111 (2013.01); C12N
15/1131 (2013.01); C12N 15/63 (2013.01);
C12N 2320/32 (2013.01); C12N 2330/51
(2013.01); C12N 2830/008 (2013.01); C12N
2830/15 (2013.01); C12N 2830/85 (2013.01)

(58) **Field of Classification Search**

CPC A61K 48/0058; C12N 15/52; C12N
2830/008

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2003/0035790 A1 * 2/2003 Chen A61K 38/208

424/85.2

2007/0166696 A1 * 7/2007 Hahn C12N 7/00

435/4

OTHER PUBLICATIONS

Ahmed, Dissertation, University of Gottingen, Gottingen, Germany,
2001.*

Dean et al, Exp. Cell. Res. 253(2):713-722, 1999.*

GeneCard, ALPP; genecards.org; last accessed Jul. 25, 2016.*

GeneCard, ALPPL2; genecards.org; last accessed Jul. 22, 2016.*

International Search Report for PCT/IB2014/061350, Sep. 3, 2014,
11 pages.

Deng et al., Transcriptional Regulation of the Human Placental-like
Alkaline Phosphatase Gene and Mechanisms Involved in Its Induc-
tion by Sodium Butyrate, American Association for Cancer
Research, 7 pages, Jun. 15, 1992.

Wada et al., Characterization of Upstream Activation Elements
Essential for the Expression of Germ Cell Alkaline Phosphatase in
Human Choriocarcinoma Cells, The Journal of Biological Chem-
istry, vol. 268, No. 19, pp. 14003-14010, Jul. 6, 1993.

Lange et al, Placental Alkaline Phosphatase as a Tumor Marker for
Seminoma, Cancer Research Journals, Nov. 9, 2015, vol. 42, pp.
3244-3247.

Kaneko et al., Adenovirus-mediated Gene Therapy of Hepatocel-
lular Carcinoma Using Cancer-specific Gene Expression, Cancer
Research Journals, Nov. 15, 1995, vol. 55, pp. 5283-5287.

Peng et al., Alpha-Fetoprotein Promoter-Driven Cre/LoxP-
Switched RNA Interference for Hepatocellular Carcinoma Tissue-
Specific Target Therapy, PLoS ONE, Feb. 2013, vol. 8, Issue 2, pp.
1-12.

Adrian L. Harris, Antiangiogenesis for cancer therapy, The Lancet,
May 1997, vol. 349, pp. 13-15.

Morris et al., Bidirectional Transcription Directs Both Transcrip-
tional Gene Activation and Suppression in Human Cells, PLoS
Genetics, Nov. 2008, vol. 4, Issue 11, pp. 1-9.

Graulich et al., Cell type specificity of the human endoglin pro-
moter, Gene Journal, 1999, vol. 227, pp. 55-62.

Wang et al., Characterization of Hypoxia-inducible Factor 1 and
Regulation of DNA Binding Activity by Hypoxia, The Journal of
Biological Chemistry, Oct. 15, 1993, vol. 268, No. 29, pp. 21513-
21518.

Mehndiratta et al., CpG Hypermethylation of the C-myc Promoter
by dsRNA Results in Growth Suppression, Molecular
Pharmaceutics, 2011, vol. 8, pp. 2302-2309.

(Continued)

Primary Examiner — Kevin Hill

(74) Attorney, Agent, or Firm — Robert D. Fish; Fish IP
Law, LLC

(57) **ABSTRACT**

The present invention relates to cell specific therapeutic
modality by using a region of the PLAP Promoter. The
invention further relates to specific expression of therapeu-
tically PLAP useful sequences for specific transcriptional
activation of this gene. The invention also relates to the
PLAP region which may be used alone or in combination
with other regions like enhancer sequences that augment cell
or tumour specific gene expression.

11 Claims, 19 Drawing Sheets